{
  "id": 6018679,
  "title": "Theranos: A journalistic investigation dismantles an empire of medical illusion",
  "url": "https://urgent.news/2026/09/05/theranos-a-journalistic-investigation-dismantles-an-empire-of-medical",
  "topic": "world",
  "section": "World",
  "published": "2026-09-05T21:00:00.000Z",
  "source": {
    "name": "Gulf Times",
    "slug": "gulf-times",
    "url": "https://www.gulf-times.com/article/732695/qatar/theranos-a-journalistic-investigation-dismantles-an-empire-of-medical-illusion"
  },
  "original_language": "en",
  "account": "The Qatar Press Centre's \"The Press: A Mirror of Truth\" series delves into journalism's power to uncover hidden truths and challenge abuses of power. In one such investigation, the media disclosed the fallacy behind Theranos, the once-celebrated health technology firm. Founded in 2003 by Elizabeth Holmes at the age of 19, Theranos aimed to revolutionize medical diagnostics with a device capable of performing hundreds of tests using mere droplets of blood. The company swiftly gained investor and media attention, boasting a valuation of $9 billion and Holmes as a symbol of innovation.\n\nHowever, the truth behind Theranos was far from glamorous. Within its own labs, several employees uncovered the device's limitations, revealing that it could not perform the majority of the tests it claimed. Witnesses like Tyler Schultz, a young researcher and Holmes' board member, and Erica Cheung, a former employee, raised concerns about the accuracy of the results. Despite these warnings, Theranos' management continued to market the device as a groundbreaking solution, painting an idealized picture of its capabilities.\n\nThe Wall Street Journal's investigative journalist John Carreyrou began questioning the company's claims in 2015 after receiving doubts about the technology's performance. Through extensive interviews and document analysis involving Schultz and Cheung, Carreyrou uncovered the reality of Theranos' operations. The company did not use its innovative devices for most tests; instead, it relied on traditional equipment from other labs and modified procedures to handle smaller samples. This revelation exposed the company's lack of precision in its testing processes, raising serious concerns about its impact on medical diagnoses and patient well-being.\n\nOn October 15, 2015, the Wall Street Journal published a damning report titled \"Theranos’ blood testing technology is in doubt.\" The article detailed how the company primarily relied on conventional lab equipment and how some tests exhibited significant inaccuracies, according to former employees and internal documents. The investigation exposed a stark contrast between the company's public image and its actual capabilities, marking Theranos as one of the most prominent fraud cases in the healthcare sector.",
  "summary": "The Qatar Press Centre (QPC) continues its \"The Press: A Mirror of Truth\" series, highlighting journalism's pivotal role in uncovering sensitive files and confidential documents.The series addres...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}